Business
United Therapeutics Corporation Reports First Quarter 2026 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., May 06, 2026--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2026. Total revenues in the first quarter of 2026 decreased by two percent year-over-year to $781.5 million, compared to $794.4 million in the first quarter of 2025.
About this update from United Therapeutics Corporation
[{"type":"text","content":"SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., May 06, 2026--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2026. Total revenues in the first quarter of 2026 decreased by two percent year-over-year to $781.5 million, compared to $794.4 million in the first quarter of 2025.","length":399,"tagName":"p"},{"type":"text","content":""In the first quarter of 2026, we extended our run of clinical success, with positive results from both our ADVANCE OUTCOMES and TETON-1 studies," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "These readouts have the potential to meaningfully expand the breadth of our future growth and support further revenue diversification while reinforcing our long-term commitment to advancing therapies for patients with serious cardiopulmonary and respiratory disease. Moreover, given these successes, we’re excited to announce our development plans in pulmonary hypertension and fibrosis for ralinepag DPI, which we believe has the potential to achieve once-daily dosing and help broaden our therapeutic reach greater than ever before."","length":798,"tagName":"p"},{"type":"text","content":"Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, added, "While the competitive landscape for inhaled prostacyclins remains dynamic, our continued growth for Tyvaso DPI reflects the resilience of our commercial strategy. Going forward, we are committed to further sharpening our execution with relentless drive and unwavering discipline to return to sequential quarterly revenue growth across our commercial portfolio in the near term."","length":477,"tagName":"p"},{"type":"text","content":"First Quarter 2026 Financial Results","length":36,"tagName":"p"},{"type":"text","content":"Key financial highlights include (dollars in millions, except per share data):","length":78,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"1","rowspan":"1","style":"vertical-align:bottom;padding-left:0.0px;width:40%;","val":[]},{"colspan":"1","rowspan":"1","style":"width:3%;","val":[]},{"colspan":"5","rowspan":"1","style":"vertical-align:bottom;padding-left:0.0px;border-bottom:solid black 1.0pt;","val":[...